← All trials
NCT02687256
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2016
- Primary completion
- Nov 30, 2017
- Completion date
- Nov 30, 2017
- First posted
- Feb 22, 2016
- Last posted
- Jun 6, 2018
- Enrollment
- 24
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Stanford UniversityLead sponsor
- Stanford UniversityOverall official - principal investigator
- Stanford UniversityReponsible party - principal investigator
- MedtronicCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.